Sound Pharmaceuticals

Sound Pharmaceuticals was founded in 2001, with the mission of developing therapies that will prevent and treat sensorineural hearing loss, as well as tinnitus. They currently have two drug candidates in clinical trials, targeting noise induced hearing loss, Meniere’s disease, as well as ototoxicity induced by chemotherapies and aminoglycosides.

Clinical Trials — Recruiting

SPI-1005 for Prevention and Treatment of Aminoglycoside Induced Ototoxicity

Condition: Ototoxicity
Intervention: Drug: Placebo; Drug: SPI-1005 Ebselen 200mg Capsule x1; Drug: SPI-1005 Ebselen 200mg Capsule x2; Drug: SPI-1005 Ebselen 200mg Capsule x3
Phase: Phase 1; Phase 2


Study to Evaluate SPI-1005 in Adults With Meniere’s Disease

Condition: Meniere’s Disease
Intervention: Drug: SPI-1005
Phase: Phase 1; Phase 2


A Phase 2b Study of SPI-1005 to Reduce the Incidence, Severity, and Duration of Acute Noise Induced Hearing Loss

Condition: Noise Induced Hearing Loss
Intervention: Drug: SPI-1005 200mg; Drug: SPI-1005 400mg; Drug: Placebo
Phase: Phase 2


SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Condition: Lung Cancer; Head and Neck Cancer; Hearing Loss; Ototoxicity; Tinnitus; Neuropathy
Intervention: Drug: SPI-1005 Low Dose; Drug: SPI-1005 Middle Dose; Drug: SPI-1005 High Dose; Drug: Placebo
Phase: Phase 2

Clinical Trials — Completed

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

Condition: Hearing Loss; Cancer
Intervention: Drug: SPI-1005; Drug: Placebo
Phase: Phase 1


Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift

Condition: Temporary Auditory Threshold Shift
Intervention: Drug: SPI-1005 Low dose; Drug: SPI-1005 Middle dose; Drug: SPI-1005 High dose; Drug: Placebo
Phase: Phase 2

RECENT NEWS ON SOUND PHARMACEUTICALS

Nothing Found

Sorry, no posts matched your criteria

COMPANY OVERVIEW

Sound Pharmaceuticals

Locations: United States
Year Founded: 2001
CEO: Eric D. Lynch (Ph.D.)